Reuben, A., Altan, M., Little, L., Zhang, J., Sheshadri, A., Tran, H. T., . . . Lizee, G. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. BMJ Publishing Group.
Chicago Style (17th ed.) CitationReuben, Alexandre, et al. High Peripheral T Cell Diversity Is Associated with Lower Risk of Toxicity and Superior Response to Dual Immune Checkpoint Inhibitor Therapy in Patients with Metastatic NSCLC. BMJ Publishing Group.
MLA (9th ed.) CitationReuben, Alexandre, et al. High Peripheral T Cell Diversity Is Associated with Lower Risk of Toxicity and Superior Response to Dual Immune Checkpoint Inhibitor Therapy in Patients with Metastatic NSCLC. BMJ Publishing Group.